Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) has received a consensus recommendation of “Buy” from the ...
Canaccord analyst Whitney Ijem lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $68 from $74 and keeps a Buy rating on the ...
Arcturus Therapeutics believes it’s “highly unlikely” it will lose the promised government funding for its bird flu mRNA ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) missed earnings with its latest annual results, disappointing overly-optimistic forecasters. Unfortunately, Arcturus Therapeutics Holdings delivered a ...
Q4 2024 Earnings Call Transcript March 6, 2025 Arcturus Therapeutics Holdings Inc. misses on earnings expectations. Reported ...
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research report issued on Friday,Benzinga reports. ARCT has been the ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $58.25, a high estimate of $63.00, ...
SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and ...
Source: Arcturus Therapeutics Holdings Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.